Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Marina Mencinger) .

1 - 10 / 16
Na začetekNa prejšnjo stran12Na naslednjo stranNa konec
1.
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
Marina Mencinger, Dushan Mangaroski, Urška Bokal, 2021, izvirni znanstveni članek

Povzetek: Background. Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.Patients and methods. 62 patients with mUC, treated at the Institute of Oncology Ljubljana between May 8th 2018 and Dec 31st 2019, were included. Response rates and immune-related adverse events (irAE) were collected. Progression-free survival and overall survival times were assessed using the Kaplan-Meier method. The Cox propor-tional hazards model was applied to identify the factors affecting survival. Results. Of 62 patients, five (8.1%) have not yet been evaluated and 20 (32%) died prior to the first radiographic evaluation. We observed clinical benefit in 19 (33%), objective response in 12 (21%), and complete response in five (9%) patients. Median overall survival for the whole population was 6.8 (95% CI, 2.6–11.0), for platinum-naïve 8.7 (95% CI: 0.8–16.5), and for the platinum-treated group 6.8 (95% CI, 3.7–10) months. At the 5.8 (0.3–23.1) month median follow-up, the median duration of the response was not reached. IrAE occurred in 20 (32%) patients and seven (11%) of them discontinued the treatment. Multivariate analysis in platinum-treated patients showed that a treatment-free interval of more than six months was prognostic for overall survival (OS). Conclusions. Responses to atezolizumab led to long disease remission in a subset of our patients. The median OS in our real-world population was compromised by a large percentage of patients with poor ECOG performance status (PS). A treatment-free interval from chemotherapy was associated with the longer survival of platinum-treated pa-tients with mUC receiving further atezolizumab.
Ključne besede: PD-L1 inhibitor, urothelial cancer, bladder, atezolizumab
Objavljeno v DiRROS: 23.07.2024; Ogledov: 111; Prenosov: 56
.pdf Celotno besedilo (718,26 KB)
Gradivo ima več datotek! Več...

2.
3.
4.
Metastatski, na kastracijo odporen rak prostate : radionuklidi, zaviralec imunskih nadzornih točk in zaviralci poli-ADP-riboza polimeraze
Marina Mencinger, 2023, objavljeni znanstveni prispevek na konferenci

Povzetek: V pričujočem prispevku opisujemo zdravila z različnim mehanizmom delovanja: radij-223 (Ra-223), lutecij-177-PSMA-167 (Lu-177-PSMA), zaviralci imunskih nadzornih točk (ZINT) ter zaviralci poli-ADP-riboza polimeraze (PARP), ki so bila v zadnjih letih registrirana s strani ameriške in/ali evropske agencije za zdravila (angl. FDA, EMA) za zdravljenje bolnikov z metastatskim, na kastracijo odpornim rakom prostate (mKORP).
Ključne besede: rak prostate, onkološko zdravljenje, kemoterapija
Objavljeno v DiRROS: 03.02.2023; Ogledov: 690; Prenosov: 150
.pdf Celotno besedilo (152,53 KB)

5.
Šola raka prostate : [strokovno srečanje]
2023, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Objavljeno v DiRROS: 02.02.2023; Ogledov: 980; Prenosov: 233
.pdf Celotno besedilo (2,61 MB)

6.
Oligometastatski rak ledvic
Marina Mencinger, 2022, objavljeni strokovni prispevek na konferenci

Ključne besede: oligometastatski raki, onkološki bolniki, obsevanje, sistemsko zdravljenje
Objavljeno v DiRROS: 14.12.2022; Ogledov: 602; Prenosov: 150
.pdf Celotno besedilo (340,38 KB)

7.
Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe : an initiative of the Central European Cooperative Oncology Group (CECOG)
Christiane Thallinger, Peter Berzinec, Emina Bicakcic, Adelina Dan, Gabriella Fabian, Laurentia Nicoletta Gales, Cvetka Grašič-Kuhar, Urška Janžič, Marina Mencinger, Christoph Zielinski, 2022, izvirni znanstveni članek

Povzetek: o establish a transborder virtual tumor board (VTB) fostering state-of-the-art management of cancer patients by exchanging knowledge and expertise among oncologists in Central and Southeastern Europe (CEE). Methods: We established and implemented a VTB based on the WebEx platform. This allowed for password-protected and secure upload of patient cases to be presented and discussed among colleagues from various oncology centers scattered throughout CEE in order to arrive at a recommendation for further diagnoses and/or treatment. Results: A total of 73 cases from 16 oncology centers located in 11 CEE countries were uploaded by 22 physicians; 71 were discussed over the course of 17 virtual meetings between June 2018 and May 2019 and 12 different kinds of malignant diseases were discussed with lung cancer (46.6%), melanoma (19.2%) and bladder cancer (13.6%) being the most commonly presented tumor entities. Of the discussed patients, 93.3% had stage IV disease at the time of presentation, 62.6% received chemotherapy or targeted treatment and 67.1% were treated with immune checkpoint inhibitors (ICPIs). The most common causes for presentation and discussion of patient cases were related to the use of ICPIs (80%). Conclusion: When the need for expertise exceeds locally available resources, web-based VTBs provide a feasible way to discuss patient cases and arrive at conclusions regarding diagnoses and/or treatment across large geographic distances. Moreover, VTBs provide an innovative way for proper, state-of-the-art management of patients with malignant diseases in times of social distancing and the resulting need for restricted interaction during the current SARS-CoV‑2 (severe acute respiratory syndrome coronavirus type 2) pandemic.
Ključne besede: CECOG, Osrednja in jugovzhodna Evropa, nadzorni imunski zaviralci, maligne bolezni
Objavljeno v DiRROS: 31.03.2022; Ogledov: 893; Prenosov: 533
.pdf Celotno besedilo (1,14 MB)
Gradivo ima več datotek! Več...

8.
9.
Podporno zdravljenje bolnikov z rakom : zbornik : osteoporoza, spolnost, plodnost in aktualne teme
2016, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Objavljeno v DiRROS: 04.08.2020; Ogledov: 2019; Prenosov: 574
.pdf Celotno besedilo (3,64 MB)

10.
Sistemsko zdravljenje bolnikov z metastatskim, na kastracijo odpornim rakom prostate
Marina Mencinger, 2019, objavljeni strokovni prispevek na konferenci

Ključne besede: rak prostate, metastatski rak, sistemsko zdravljenje
Objavljeno v DiRROS: 11.05.2020; Ogledov: 1921; Prenosov: 561
.pdf Celotno besedilo (66,80 KB)

Iskanje izvedeno v 0.55 sek.
Na vrh